Orchestra BioMed (NASDAQ:OBIO) Raised to “Hold” at Wall Street Zen

Orchestra BioMed (NASDAQ:OBIO – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Several other equities research analysts also recently weighed in on OBIO. HC Wainwright boosted their target price on shares of Orchestra BioMed from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday. BTIG Research boosted their price target on shares of Orchestra BioMed from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday. B. Riley Financial boosted their price objective on Orchestra BioMed from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Weiss Ratings upgraded shares of Orchestra BioMed from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 10th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Orchestra BioMed in a research report on Thursday, October 15th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Orchestra BioMed presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.29.

View Our Latest Stock Analysis on OBIO

Orchestra BioMed Price Performance

Shares of NASDAQ:OBIO opened at $7.25 on Friday. Orchestra BioMed has a 12-month low of $3.46 and a 12-month high of $7.37. The stock’s 50-day moving average price is $5.86 and its two-hundred day moving average price is $4.63. The firm has a market cap of $445.53 million, a price-to-earnings ratio of -9.67 and a beta of 0.56. The company has a current ratio of 7.25, a quick ratio of 7.24 and a debt-to-equity ratio of 4.58.

Orchestra BioMed (NASDAQ:OBIO – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.10. Orchestra BioMed had a negative return on equity of 186.93% and a negative net margin of 182.50%. The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.13 million. On average, research analysts forecast that Orchestra BioMed will post -1.46 EPS for the current year.

Insider Buying and Selling

In related news, Director David Pacitti acquired 20,000 shares of the business’s stock in a transaction on Monday, November 9th. The stock was bought at an average cost of $5.00 per share, with a total value of $100,000.00. Following the completion of the acquisition, the director owned 74,750 shares in the company, valued at $373,750. The trade was a 36.53% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David Hochman purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The stock was acquired at an average cost of $4.79 per share, with a total value of $47,900.00. Following the completion of the acquisition, the insider directly owned 1,070,746 shares of the company’s stock, valued at $5,128,873.34. The trade was a 0.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have purchased 58,000 shares of company stock valued at $288,560 and have sold 45,000 shares valued at $255,600. Company insiders own 7.50% of the company’s stock.

Hedge Funds Weigh In On Orchestra BioMed

Large investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Orchestra BioMed during the 2nd quarter valued at $10,832,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Orchestra BioMed during the second quarter worth approximately $2,771,000. Rice Hall James & Associates LLC bought a new position in shares of Orchestra BioMed in the second quarter worth $1,830,000. Flat Footed LLC acquired a new position in shares of Orchestra BioMed in the 2nd quarter valued at approximately $1,084,670. Finally, Knott David M Jr lifted its stake in Orchestra BioMed by 1.5% during the first quarter. Knott David M Jr now owns 253,651 shares of the company’s stock worth $1,078,000 after purchasing an additional 3,651 shares during the last quarter. 53.20% of the stock is currently owned by institutional investors and hedge funds.

About Orchestra BioMed

(Get Free Report)

Orchestra BioMed is a medical technology company that develops therapies for cardiovascular and other diseases, often in collaboration with established medical-device companies. Its work focuses on technologies intended to integrate with existing treatment approaches and devices. The company’s lead program, AVIM therapy, is designed to lower blood pressure in people with pacemakers by adjusting the timing of cardiac pacing. Orchestra BioMed is also developing Virtue SAB, a drug-delivery balloon intended to treat coronary artery disease by delivering sirolimus to blood vessels.

Further Reading

Analyst Recommendations for Orchestra BioMed (NASDAQ:OBIO)

Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.